Silo Pharma, Inc.

SILO

US82711P2011

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 21/06/2024 BST			5-day change	1st Jan Change
0.98 ^USD	-0.83%		-10.91%	-31.94%

06-11	Silo Pharma, Inc. announced that it has received $2.077409 million in funding	CI
06-07	Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant	MT

Silo Pharma, Inc. announced that it expects to receive $2.077409 million in funding

June 03, 2024

Silo Pharma, Inc. announced that it will receive $2,077,409 in funding on June 4, 2024. The company will issue Convertible Preferred Stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D.

Latest news about Silo Pharma, Inc.

Silo Pharma, Inc. announced that it has received $2.077409 million in funding	06-10	CI
Silo Pharma Close to Achieving Optimal Formulation for Ketamine Implant	06-07	MT
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia	06-07	CI
Top Midday Decliners	06-05	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	06-04	MT
Silo Pharma Submits Pre-Investigational NDA For PTSD, Anxiety Treatment; Shares Rise	06-04	MT
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety	06-04	CI
Silo Pharma, Inc. announced that it expects to receive $2.077409 million in funding	06-03	CI
Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	05-21	CI
Silo Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	04-23	CI
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	04-10	MT
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	04-05	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04-03	CI
Tranche Update on Silo Pharma, Inc.'s Equity Buyback Plan announced on January 31, 2023.	03-25	CI
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	03-20	CI
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	03-18	CI
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	02-14	CI
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	02-01	CI
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	01-24	CI
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	01-08	CI
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	01-04	CI
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	12-28	MT
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	12-28	CI

Chart Silo Pharma, Inc.

Duration

Period

More charts

Company Profile

Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Companyâs lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimerâs disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SILO PHARMA, INC.	-31.94%	3.64M
CSL LIMITED	+2.22%	93.53B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	38.27B
BIOGEN INC.	-13.44%	32.84B
UCB	+76.30%	27.83B
BIOMARIN PHARMACEUTICAL INC.	-13.11%	16.08B
INCYTE CORPORATION	+0.68%	14.02B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.06%	11.47B
ALTEOGEN INC.	+185.28%	9.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.00%	9.42B

Biopharmaceuticals

Silo Pharma, Inc.

Equities

SILO

US82711P2011

Pharmaceuticals

Silo Pharma, Inc. announced that it expects to receive $2.077409 million in funding

Latest news about Silo Pharma, Inc.

Chart Silo Pharma, Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals